| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1005217455 |
| P356 | DOI | 10.1186/1744-8069-10-54 |
| P932 | PMC publication ID | 4237902 |
| P698 | PubMed publication ID | 25183392 |
| P5875 | ResearchGate publication ID | 265343209 |
| P2093 | author name string | Christopher H Evans | |
| Aravind Asokan | |||
| Andreas S Beutler | |||
| Josef Pleticha | |||
| Lukas F Heilmann | |||
| Richard Jude Samulski | |||
| P2860 | cites work | Cancer-related chronic pain: examining quality of life in diverse cancer survivors | Q48686500 |
| A method to perform direct transcutaneous intrathecal injection in rats. | Q50767149 | ||
| Plasma beta-endorphin levels during obstetrical analgesia with synthetic beta-endorphin. | Q51814419 | ||
| beta-Endorphin in obstetric analgesia. | Q51875688 | ||
| Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. | Q52958415 | ||
| High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. | Q54049336 | ||
| Safety Assessment and Pharmacokinetics of Intrathecal Methylprednisolone Acetate in Dogs | Q60680923 | ||
| Intrathecal administration of beta-endorphin and dynorphin-(1-13) for the treatment of intractable pain | Q69870624 | ||
| Lumbar catheterization of the spinal subarachnoid space in the rat | Q71346801 | ||
| Cytokine involvement in dynorphin-induced allodynia | Q73427482 | ||
| Long-term opioid management for chronic noncancer pain | Q24240811 | ||
| Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10 | Q24796221 | ||
| Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats | Q25256466 | ||
| Spinal interleukin-10 therapy to treat peripheral neuropathic pain | Q26861391 | ||
| Adeno-associated virus: from defective virus to effective vector | Q27498163 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain | Q28583865 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy | Q30541880 | ||
| Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. | Q31917601 | ||
| Investigation of the cause of death in a gene-therapy trial | Q33385315 | ||
| Targeted delivery of pharmacological agents into rat dorsal root ganglion | Q33386453 | ||
| PEGylation of interleukin-10 for the mitigation of enhanced pain states | Q33505369 | ||
| Safety and tolerability of putaminal AADC gene therapy for Parkinson disease | Q33731687 | ||
| The effects of opioids and opioid analogs on animal and human endocrine systems | Q33779667 | ||
| Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons | Q33822237 | ||
| Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group | Q33927770 | ||
| Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture | Q33975660 | ||
| β-Endorphin: Analgesic and hormonal effects in humans | Q34039519 | ||
| Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain | Q34142832 | ||
| Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. | Q34153746 | ||
| Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. | Q34153943 | ||
| A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease | Q34209755 | ||
| Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial | Q34311144 | ||
| Long-term follow-up after gene therapy for canavan disease. | Q34318553 | ||
| Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector | Q34633598 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| Loss of Siglec expression on T lymphocytes during human evolution | Q34650845 | ||
| Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 | ||
| Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. | Q34684229 | ||
| Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. | Q34778098 | ||
| Self-complementary AAV vectors; advances and applications | Q34804660 | ||
| Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates | Q35086714 | ||
| Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. | Q35105022 | ||
| Gene therapy for pain: results of a phase I clinical trial | Q35154100 | ||
| Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates | Q35568563 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Dorsal root ganglion - a potential new therapeutic target for neuropathic pain | Q35780942 | ||
| The AAV vector toolkit: poised at the clinical crossroads | Q35876224 | ||
| Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates | Q35892068 | ||
| Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease | Q35932749 | ||
| Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury | Q36149890 | ||
| A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's Guide | Q36302851 | ||
| Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain | Q36458975 | ||
| Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates | Q36745664 | ||
| Arthritis gene therapy's first death | Q36790320 | ||
| Intrathecal opioids for intractable pain syndromes | Q36906965 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients | Q37027502 | ||
| Direct injection into the dorsal root ganglion: technical, behavioral, and histological observations. | Q37091212 | ||
| Minimally invasive convection-enhanced delivery of biologics into dorsal root ganglia: validation in the pig model and prospective modeling in humans. Technical note | Q37342392 | ||
| Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery | Q37355740 | ||
| Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. | Q37358381 | ||
| Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain | Q37398172 | ||
| AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction | Q37571781 | ||
| A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. | Q37895002 | ||
| Gene therapy clinical trials worldwide to 2012 - an update. | Q38077166 | ||
| Opioids and immune modulation: more questions than answers. | Q38116502 | ||
| Epidural beta-endorphin in treatment of pain | Q39565481 | ||
| Profound analgesic effects of beta-endorphin in man. | Q39572686 | ||
| Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease | Q39863620 | ||
| Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors | Q39884792 | ||
| Preclinical safety evaluation of recombinant human interleukin-10. | Q40659986 | ||
| Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers | Q40673185 | ||
| Side effects of intrathecal and epidural opioids | Q41032129 | ||
| Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts. | Q41373501 | ||
| Complications of lumbar puncture | Q41676436 | ||
| Pig lumbar spine anatomy and imaging-guided lateral lumbar puncture: a new large animal model for intrathecal drug delivery | Q41906903 | ||
| Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial | Q42228547 | ||
| A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease | Q42244023 | ||
| scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease | Q42288269 | ||
| Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response | Q42450986 | ||
| A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. | Q42472539 | ||
| Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial | Q42650874 | ||
| Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion | Q43586557 | ||
| Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort | Q43996458 | ||
| A procedure for direct lumbar puncture in rats | Q44216413 | ||
| The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). | Q44339922 | ||
| Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors | Q44492885 | ||
| Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum | Q44631221 | ||
| AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection | Q44655971 | ||
| Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats | Q44658624 | ||
| Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. | Q44899252 | ||
| Gene therapy for aromatic L-amino acid decarboxylase deficiency | Q45215332 | ||
| Gene targeting in vivo by adeno-associated virus vectors. | Q45413871 | ||
| Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid | Q45414481 | ||
| AAV vector integration sites in mouse hepatocellular carcinoma. | Q45869780 | ||
| Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. | Q45883209 | ||
| Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates | Q45889555 | ||
| Kinetic and safety studies on intrathecally infused recombinant-methionyl human brain-derived neurotrophic factor in dogs. | Q45986732 | ||
| Intrathecal catheterization and drug delivery in the rat. | Q46561414 | ||
| Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide | Q47699203 | ||
| Magnetic positioning system and ultrasound guidance for lumbar zygapophysial radiofrequency neurotomy: a cadaver study | Q47940132 | ||
| Immune responses to AAV in a phase I study for Canavan disease | Q48620414 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | analgesic | Q173235 |
| gene therapy | Q213901 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 54 | |
| P577 | publication date | 2014-09-02 | |
| P1433 | published in | Molecular Pain | Q15766244 |
| P1476 | title | Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs | |
| P478 | volume | 10 |
| Q48510056 | AAVrh.10-mediated APOE2 CNS Gene Therapy for APOE4-associated Alzheimer's Disease |
| Q38826202 | Beyond the brain: Optogenetic control in the spinal cord and peripheral nervous system |
| Q47131605 | Experimental Gene Therapy with Serine-Histogranin and Endomorphin 1 for the Treatment of Chronic Neuropathic Pain. |
| Q39011240 | Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors. |
| Q38559511 | Gene therapy and peripheral nerve repair: a perspective. |
| Q27313762 | Soft, stretchable, fully implantable miniaturized optoelectronic systems for wireless optogenetics. |
| Q39179183 | Switching off pain at the source: is this the end for opioid pain relief? |
| Q89634678 | Viral Vector-Mediated Gene Transfer of Glutamic Acid Decarboxylase for Chronic Pain Treatment: A Literature Review |
| Q33840501 | [EXPRESS] Primary sensory neuron-specific interference of TRPV1 signaling by AAV-encoded TRPV1 peptide aptamer attenuates neuropathic pain |
| Q41544495 | [EXPRESS]Analgesia by Deletion of Spinal Neurokinin 1 Receptor Expressing Neurons Using a Bioengineered Substance P-Pseudomonas Exotoxin Conjugate. |
| Q38668241 | microRNA and Pain |
Search more.